Daxor Corporation DXR

Full chart Compare
Set alert

Price alert · DXR

All alert types
8.70 USD -0.30 (-3.33%)

At closeNov 3, 2026, 4:00 PM EST

9.19 +0.49 +5.63%

After hours · Nov 3, 4:00 PM ET

8.50 Day range 8.95
8.40 52-week range 14.76
YTD
-41.02%
1 year
-33.54%
Market cap
50.79M
Revenue (ttm)
154.21K
Profit margin
1094.00%
EPS (ttm)
1.13
Shares out
4.84M
P/E ratio
7.70
YTD return
-41.02%
1-year return
-33.54%
Volume
36.11K
Avg volume
20.03K
Open
8.89
Previous close
9.00
Day's range
8.50 – 8.95
52-week range
8.40 – 14.76
Beta
-0.54
Price target
23.38 (+168.7%)
Earnings date
Mar 28, 2012

6M -1.42 (-14.03%)

91011May 21Jun 29Aug 5Sep 10Oct 158.70

Key statistics

Enterprise value
0
PEG ratio
0.00
Price / sales
260.51
Price / book
1.23
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-11.40%
Free cash flow
0
Total cash
0
Total debt
1.65M
Return on equity
5.35%
Short % of float
0.71%
50-day average
8.96
200-day average
9.04

Financials — quick view

All financials
DXR Revenue — quarterly 369.83K
2008-Q1 20082008-Q2 20082008-Q3 20082008-Q4 20082009-Q1 20092009-Q2 20092009-Q3 20092009-Q4 20092010-Q1 20102010-Q2 20102010-Q3 20102010-Q4 20102011-Q1 20112011-Q2 20112011-Q3 20112011-Q4 2011
DXR Net income — quarterly -1.49M
2008-Q1 20082008-Q2 20082008-Q3 20082008-Q4 20082009-Q1 20092009-Q2 20092009-Q3 20092009-Q4 20092010-Q1 20102010-Q2 20102010-Q3 20102010-Q4 20102011-Q1 20112011-Q2 20112011-Q3 20112011-Q4 2011
DXR EPS — quarterly -0.36
2008-Q1 20082008-Q2 20082008-Q3 20082008-Q4 20082009-Q1 20092009-Q2 20092009-Q3 20092009-Q4 20092010-Q1 20102010-Q2 20102010-Q3 20102010-Q4 20102011-Q1 20112011-Q2 20112011-Q3 20112011-Q4 2011

Earnings

DXR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 28, 2012Dec 1, 20110.00———
Nov 14, 2011Sep 1, 20110.00———

Upgrades / downgrades

DXR analyst upgrades and downgrades
DateFirmActionFromTo
Sep 9, 2024Ascendiant CapitalmainBuyBuy
Jul 29, 2019Maxim Groupinit—Buy
May 16, 2019Ascendiant Capitalinit—Buy

About Daxor Corporation

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Website
daxor.com

News

Your note

Sign in to keep a note on DXR — it syncs with the Stock Master app.

Insider holders

DXR insider holders
InsiderRelationLatest transactionDateShares held
FELDSCHUH JONATHAN ADAMOfficer and DirectorPurchaseDec 5, 202435,908
FELDSCHUH MICHAEL RICHARDChief Executive OfficerPurchaseDec 5, 2024207,492
FEUER EDWARDDirectorPurchaseMar 3, 20241,000
GOUDIE JOY SDirectorPurchaseMay 23, 2023300
JOSEPH FELDSCHUH UEOTrusteeStock GiftSep 17, 20232,549,460
MICHEL ROBERT JChief Financial OfficerPurchaseMar 26, 202411,300

Institution ownership

DXR institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc1.01%48,828405.27KSep 29, 2024
Renaissance Technologies, LLC0.31%14,821123.01KSep 29, 2024
Keyes, Stange & Wooten Wealth Management, LLC 0.30%14,612121.28KSep 29, 2024
Osaic Holdings Inc0.15%7,20059.76KSep 29, 2024
UBS Group AG0.03%1,23610.26KSep 29, 2024
Princeton Global Asset Management LLC0.01%5004.15KSep 29, 2024

Fund ownership

DXR fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.01%48,828405.27KSep 29, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.13%6,30552.33KSep 29, 2024
Gabelli Global Mini Mites Fund0.01%4003.32KSep 29, 2024
Northern Small Cap Core Fund0.00%37307Sep 29, 2024